A series of novel 2-aryl-5-((1-aryl-1H-1,2,3-triazol-4-yl)methylthio)-1,3,4-oxadiazoles have been synthesised by C–S bond formation and azide–alkyne cyclocondensation between [5-(aryl)-[1,3,4]oxadiazol-2-yl]methanethiol, propargyl bromide, and substituted aryl azides in one pot with an aim to explore their effect on the in vitro growth of microorganisms causing microbial infection. In vitro antibacterial activity was determined against four strains, namely Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa and antifungal activity against two fungal strains, namely Aspergillus niger and Aspergillus flavus.